Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.24 and traded as high as $1.64. Cortexyme shares last traded at $1.64, with a volume of 27,429 shares traded.
Cortexyme Stock Up 0.6 %
The stock has a market capitalization of $48.54 million, a price-to-earnings ratio of -0.54 and a beta of 1.40. The business’s 50-day moving average is $1.85 and its two-hundred day moving average is $1.24.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
See Also
- Five stocks we like better than Cortexyme
- How to Choose Top Rated Stocks
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- What is a SEC Filing?
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
